Barchas Isaac 4

What Happened

• Isaac Barchas, a director of Immunome Inc. (IMNM), was granted a 9,897-share equity award (reported as a derivative) on June 10, 2026. The filing reports an acquisition price of $0 and a total reported value of $0. The award is subject to vesting and is being held for the benefit of Arsenal Bridge Ventures; Mr. Barchas disclaims beneficial ownership.

Key Details

• Transaction date: 2026-06-10 (report filed 2026-06-12; appears filed within the standard 2-business-day window).
• Transaction type/code: Award/Grant (A) of a derivative security.
• Reported price/value: $0.00 per share; reported total $0.
• Vesting: The option vests in four equal quarterly installments beginning June 10, 2026 and completing on the one-year anniversary (subject to continued service).
• Shares owned after transaction: filing indicates the securities are held for Arsenal Bridge Ventures and Mr. Barchas disclaims beneficial ownership (no personal beneficial ownership reported).
• Footnotes: F1 — securities granted are held for the benefit of Arsenal Bridge Ventures; F2 — vesting schedule described above.

Context

• This was an equity award subject to vesting (a derivative grant), not an open-market purchase or sale — the shares are not immediately freely tradable. Because the award is held for Arsenal Bridge Ventures and Mr. Barchas disclaims beneficial ownership, the economic/ownership interest is attributed to that entity rather than to him personally.
• Such board-service awards are common and do not by themselves indicate the insider’s personal buying or selling sentiment.